Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

Maria Isabel Sotelo-Alva; Ofrat Beyar-Katz; Judy Yan; Silvia Escribano-Serrat; Alexander P. Boardman; Mika Geva; Marina Gomez-Llobell; Jabour Halloun; Hazim Khatib; Malin Hultcrantz; Jennifer Kimberly Lue; Sham Mailankody; Genovefa Papanicolaou; Lia Palomba; Jae H Park; Kai Rejeski; Jaime Sanz; Michael Scordo; Susan K. Seo; G. L. Shah; Kayleen Shi; Niveen Shibli; S. Z. Usmani; Noriko Nishimura; Zainab Shahid; Miguel-Angel Perales; Roni Shouval; Mini Kamboj; Sigrun Einarsdottir

doi:10.1093/cid/ciag052

Key Points

This research aims to identify risk factors and outcomes related to respiratory syncytial virus (RSV) in patients receiving CAR T-cell therapy.
Retrospective cohort study of 667 CAR T-cell therapy recipients.
Assessment of RSV incidence and progression to long-term respiratory tract infection (LRTI).
Analysis of associations between age and lymphopenia with RSV severity.
2-year cumulative incidence of RSV was 7% among the cohort.
29% of RSV cases progressed to long-term respiratory tract infection (LRTI).
74% of infections occurred after day +100, with a median onset of 8 months.

Implication

A multicenter retrospective cohort analyzes RSV risk factors and outcomes in CAR T-cell recipients, indicating clinical vigilance is needed during RSV season.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sotelo-Alva et al. (2026) studied this question.

synapsesocial.com/papers/699fe38b95ddcd3a253e77af https://doi.org/10.1093/cid/ciag052

View Full Paper

Ask AI

Bookmark

Share

Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

Key Points

Implication

Discussion

Cite This Study

Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading